You are here: Industry Insights > Tychan

News List

WuXi Biologics Congratulates Tychan on Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers En-CPhI.CN
November 19, 2019
WuXi Biologics congratulates its partner Tychan on successful completion of the Phase 1A/1B safety and efficacy trials in Singapore for TY014, a first-in-class monoclonal antibody candidate treatment for Yellow Fever (YF).
World's First Candidate Antibody Treatment for Yellow Fever, Developed by Tychan, Tested Safe and Effective in Human Volunteers En-CPhI.CN
November 15, 2019
Tychan's first-in-class monoclonal antibody candidate treatment for Yellow Fever (YF), called TY014, has successfully completed Phase 1A/1B safety trials in Singapore, it announced.
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development en-cphi.cn
December 13, 2018
WuXi Biologics congratulates its partner Tychan for dosing of first individual in phase 1 trial of TY
Tychan Completes Human Safety Studies for Monoclonal Antibody against Zika americanpharmaceuticalreview
October 30, 2018
Tychan has successfully completed Phase-1 safety trials for Tyzivumab, its first-in-class monoclonal antibody (mAb) therapeutic for Zika, in Singapore.